Ensysce Biosciences Inc (ENSC)
Ensysce Biosciences, Inc. is a clinical-stage biotechnology company focused on developing prescription medicines for severe pain and on addressing opioid misuse, abuse, and overdose in the United States. Its drug development programs are built around two technology platforms: Trypsin Activated Abuse Protection (TAAP), which is intended to release an active drug only under specific physiological conditions, and Multi-Pill Abuse Resistance (MPAR), an overdose-protection prodrug approach. The company’s lead candidate is PF614, a TAAP-based oxycodone prodrug being developed for severe or chronic pain. Ensysce is also advancing PF614-MPAR, a combination of PF614 and nafamostat, for overdose protection, along with PF8001 and PF8026 for attention deficit hyperactivity disorder and PF9001 for opioid use disorder. Founded in 2003, the company is based in La Jolla, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ENSC
|
$0.43
|
57.8% Upside
|
Bargain
|
$16.45 5,936.7% Upside
|
—
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-0.3x
|
-11.8x
|
0.9x
|
3.963 M
|
3.174 M
|
6.3%
|
99.9%
|
-108.0
|
—
|
82.5%
|
